Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.
about
Clinical review: Treatment of heat stroke: should dantrolene be considered?Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3Structural and functional characterization of ryanodine receptor-natrin toxin interactionLong-term dantrolene treatment reduced intraneuronal amyloid in aged Alzheimer triple transgenic micePharmacokinetic evaluation of oral dantrolene in the dog.Ryanodine receptors: structure, expression, molecular details, and function in calcium release.Cooling methods used in the treatment of exertional heat illnessSpasticity management in the child with spastic quadriplegia.Dantrolene reduces the threshold and gain for shiveringThe treatment of neuroleptic malignant syndrome using dantrolene sodium.Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.Dantrolene prevents arrhythmogenic Ca2+ release in heart failureBench-to-bedside review: mechanisms and management of hyperthermia due to toxicityMobilization of dantrolene-sensitive intracellular calcium pools is involved in the cytotoxicity induced by quisqualate and N-methyl-D-aspartate but not by 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionate and kainate in cultured cerebral corticDeranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2.Targeting calcium transport in ischaemic heart disease.The effect of long-term oral dantrolene on the neuromuscular action of rocuronium: a case report.The underutilization of intrathecal baclofen in poststroke spasticity.Themes and variations in ER/SR calcium release channels: structure and function.Pharmacologic effects on thermoregulation: mechanisms of drug-related heatstroke.Emerging pathways driving early synaptic pathology in Alzheimer's disease.Pleural effusion associated with chronic dantrolene administration.Malignant hyperthermia. Epidemiology, pathophysiology, treatment.Role of intracellular calcium stores in cell death from oxygen-glucose deprivation in a neuronal cell line.Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.TrkA mediates the nerve growth factor-induced intracellular calcium accumulation.Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis.Probing a putative dantrolene-binding site on the cardiac ryanodine receptorCa2+-activated K+ currents in rat locus coeruleus neurons induced by experimental ischemia, anoxia, and hypoglycemia.Metoclopramide increases the bioavailability of dantrolene in spinal cord injury.Early postischemic dantrolene-induced amelioration of poly(ADP-ribose) polymerase-related bioenergetic failure in neonatal rat brain slices.Dantrolene sodium reverses the increase in cAMP response element and TPA responsive element DNA-binding activity in the rabbit brain following haloperidol administration and heat stress.Inherited muscle and brain channelopathies.Properties of ryanodine receptors in cultured cerebellar granule neurons: effects of hexachlorocyclohexane isomers and calcium.Effects of calcium antagonists on rat normal and skinned fundus.Can dantrolene contribute to methotrexate toxicity?
P2860
Q24801946-45EBCBAA-CBCB-44AA-8DAB-92395C338C52Q28575230-A1C81BAE-91C7-4773-A43C-79D38D361378Q30484109-D536342C-21A4-4EF1-BE9C-351CA8991661Q30887483-3BC59C72-031B-4650-8B2B-B62CE506F923Q33988845-9E6C15F7-2242-4BF3-8B44-23CE436CB8A4Q34024377-353CF8A1-3732-42AF-B339-1DAB90DBED8FQ34437330-A268F892-EEC4-4A62-B290-420B24AC6523Q34536063-5DC79412-F9BE-4BD2-AAC7-2C36F4FE6CC2Q34583099-9F10EC57-9376-4A1A-B86D-DA02C02B6778Q34753870-EB2E2B81-D70A-46AB-9975-4368C9CC2009Q35166725-2F4E928D-4FA4-4B15-879A-7D3BA53C0186Q35879180-A6FC4ED3-AB80-4A3E-AEAE-12AA13D1A115Q36465395-34957B5E-8AAD-4991-950E-B60B87CE0040Q36911035-F6FE2590-A25E-4B5A-8577-15F1C3B3DF69Q37359666-5D7CE8D2-F279-49D9-A625-5B645C6A8335Q37422613-91654A54-94DA-46CB-A9F1-0B5C97DEDEDCQ37628249-CC148CC0-17F0-42F9-B164-033AF63DF9B3Q37885039-6BDAAE64-113B-4390-BA43-3EAE2E72F2A9Q38065938-0F762AE9-8232-4597-B44D-694A2970502AQ38741814-B587F6C9-D7F2-4B0B-B931-95E668C6D22CQ38962140-5B54A9F2-A01F-4238-88AF-484F354C2D05Q40693697-134B3995-B43B-4694-9511-E40DE0080EBFQ40735165-531F7B1C-1C00-4E71-A15B-EF3AA649C548Q40753077-814A4836-98D6-448F-8EAD-370987C45FF2Q40817461-58F147A0-8D09-4502-9FE8-B96C4FB19508Q41216085-B2F1FF2E-114A-46DB-B555-2AC0179F0E9EQ41976836-BAC063B3-519B-4746-BB2A-1832CA9A82DAQ42101961-EBB5EC2A-50F4-4239-BA36-2AF8D4F6CF6AQ42446490-9B595BB1-A930-45E7-96BD-8369947B294AQ46650900-EC4ECEF4-220F-45B4-B152-8090E4A2AD83Q48331055-7DC21ABD-B8FB-44E1-A8E1-78B57BB4F044Q48530447-E965745D-53A0-408A-B9AD-73FD2164CB9CQ48725401-741263C8-8CA2-44E5-BD89-F2E081A780DAQ48824285-B7A722EA-9A1B-4EA5-A6AE-1187336F5CDFQ53845555-FF392E94-AE6B-45FE-B0A7-D595F04A9647Q54218642-3367CAC3-FB69-4CC4-A534-4219DFE4B13C
P2860
Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Dantrolene. A review of its ph ...... its use in muscle spasticity.
@en
Dantrolene. A review of its ph ...... its use in muscle spasticity.
@nl
type
label
Dantrolene. A review of its ph ...... its use in muscle spasticity.
@en
Dantrolene. A review of its ph ...... its use in muscle spasticity.
@nl
prefLabel
Dantrolene. A review of its ph ...... its use in muscle spasticity.
@en
Dantrolene. A review of its ph ...... its use in muscle spasticity.
@nl
P2093
P1433
P1476
Dantrolene. A review of its ph ...... its use in muscle spasticity.
@en
P2093
P304
P356
10.2165/00003495-198632020-00003
P577
1986-08-01T00:00:00Z
P6179
1001631547